Kyverna Therapeutics is progressing its drug mivocabtagene autoleucel for autoimmune diseases, targeting approval for stiff person syndrome. Updated trial data show all 26 patients stopped chronic immunotherapies at 16 weeks, with 81% reporting improved mobility, boosting regulatory confidence. The company is submitting a rolling Biologics License Application, aiming for completion by late 2026 and potential approval by mid-2027, with key phase 2/3 data in myasthenia gravis expected soon. Kyverna's cash runway extends into 2028, but a significant equity raise may be needed in 2027 due to a narrow margin before commercialization and a limited initial market size.
Bureau Veritas disclosed its share buyback transactions conducted between October 5 and October 9, 2026. This activity reflects the company's ongoing efforts to manage its capital structure and potentially enhance shareholder value. Investors should ...
In Q3 2026, TRON DAO reported a milestone of $2.21 trillion in stablecoin settlements, with the network surpassing $30 trillion in cumulative transaction volume. The active user base grew by nearly 10%, and stablecoin supply increased to $93.88 billi...
Bureau Veritas disclosed its treasury shares transactions conducted between October 5 and October 9, 2026. This update is part of the company's regular reporting obligations to inform investors about changes in its treasury shares holdings. Such disc...
Pepeto, a new Ethereum-based cryptocurrency, has launched its page on CoinMarketCap, indicating a Binance listing is near. The project features a working bridge across Ethereum, BNB Chain, and Solana, with zero-cost token transfers and AI contract ch...
Crédit Agricole has signed an agreement to acquire 100% of IKB Deutsche Industriebank, a key financier for Germany's Mittelstand companies. This acquisition strengthens Crédit Agricole's expansion in Germany, Europe's largest economy, aligning with i...
